Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?

Kool, Ronald; Marcq, Gautier; El-Achkar, Adnan; Mansure, José João; Vanhuyse, Marie; Aprikian, Armen; Tanguay, Simon; Cury, Fabio; Brimo, Fadi; Souhami, Luís; Kassouf, Wassim

doi:10.1016/j.urolonc.2020.10.001

Cited by 5 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A complete response (CR) was defined by a negative tumor bed biopsy (or the combination of negative urine cytology and normal cystoscopy for patients who did not undergo a control biopsy) within 3 mo after RT, with no signs of locoregional disease or distant metastasis on cross-sectional imaging. A 3-mo cutoff for CR was deemed appropriate to differentiate persistent disease from early relapse [13] . OS was measured from the date of first treatment to the date of death due to any cause.…”

Section: Methodsmentioning

confidence: 99%

Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy

Marcq¹,

Evaristo²,

Kool³

et al. 2022

European Urology Open Science

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy

Marcq¹,

Evaristo²,

Kool³

et al. 2022

European Urology Open Science

View full text Add to dashboard Cite

“…In fact, a recent single-center retrospective study on patients with MIBC (cT2-4aN0-2M0) treated with curative intent RT assessed the role of tumor bed biopsy. 49 Although the large majority of patients were correctly staged with cystoscopy, the authors reported a 5% rate of residual MIBC in optically normal bladders post TMT. In fact, Yoshida et al 50 in 2010 included in a small prospective study (n = 20) T2-4aN0M0 MIBC patients who underwent induction 'low-dose' chemoradiotherapy (40 Gy with concomitant 2 cycles of cisplatin) followed by partial (n = 13) or radical cystectomy (n = 7).…”

Section: Response To Neoadjuvant Therapiesmentioning

confidence: 96%

Section: Vi-rads Score and Bladder Mpmri Potential Clinical Applicati...mentioning

confidence: 96%

Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications

Séguier

Puech

Kool

et al. 2021

Therapeutic Advances in Urology

Self Cite

View full text Add to dashboard Cite

Background: The Vesical Imaging-Reporting and Data System (VI-RADS) score is a novel standardized approach to image and report bladder cancer (BC) with multiparametric MRI (mpMRI). Objectives: To describe and evaluate the performance of the VI-RADS score using mpMRI and assess its potential clinical applications and limitations. Methods: A systematic review was conducted using the MEDLINE and EMBASE electronic bibliographic databases between June 2020 and December 2020. All reports deemed relevant to describe the VI-RADS score and assess its performance and applications were retrieved. Results presentation stands as narrative, purely descriptive synthesis based on aggregate studies data. Results: A total of 20 relevant studies were retrieved: three meta-analyses, five prospective studies, and twelve retrospective studies. The retrospective studies covered 1676 patients, while the prospective studies included a total number of 468 patients. Pooled sensitivity, specificity to differentiate muscle-invasive from non-muscle-invasive bladder cancer, ranged from 74.1% to 97.3%, and 77% to 100%, respectively. The chosen VI-RADS score thresholds for this discrimination varied across studies. The interreader agreement ranged from 0.73 to 0.95. Currently, the potential clinical applications of VI-RADS consist of initial BC risk stratification, assessment of neoadjuvant therapies response, and bladder sparing approaches, although further validation is required. Conclusions: The VI-RADS score helps to discriminate muscle invasive from non-muscle invasive BC with good performance and reproducibility. A simple algorithm based on four basic questions may enhance its popularization. Further studies are required to validate the clinical applications.

show abstract

“…В группе больных, у которых имелись положительные данные цитологии или подозрительные цистоскопические участки, опухолевый процесс верифицирован в 55 % случаев. Многофакторный анализ показал, что возраст (ОР 1,04; р <0,001), лимфоваскулярная инвазия (ОР 1,68; р = 0,03) и подозрительные изменения при цистоскопии после ХЛТ (ОР 3,21; р <0,001) отрицательно влияли на ОВ [95].…”

Section: оценка эффективности и диспансерное наблюдение после тримода...unclassified

Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021)

Novikov

Новиков

et al. 2022

Onkourologiâ

View full text Add to dashboard Cite

The aim of this work was to clarify and extend the existing clinical guidelines on organ-sparing treatment of muscleinvasive bladder cancer. The standard protocol of radical conservative treatment for muscle-invasive bladder cancer includes transurethral resection of the bladder, external beam radiotherapy with simultaneous chemotherapy (radiosensitization), which is usually referred to as trimodal therapy. The implementation of trimodal therapy into routine practice in Russia is limited due to the lack of distinct criteria for each of the stages. The involvement of surgeons, radiation oncologists, and chemotherapists, on the one hand, provides the required multidisciplinary approach to cancer treatment; on the other hand, it might impede the entire algorithm. To address this problem, specialists from the Department of Radiology (project moderators), Department of Cancer Urology, and Department of Chemotherapy of N.N. Petrov National Medical Research Center of Oncology under the auspices of Saint Petersburg Oncological Research Society formed a group of experts, including radiation oncologists, urologists, and chemotherapists from federal and local cancer (educational) institutions of Saint Petersburg who had an experience of treating muscle-invasive bladder cancer. The guideline was developed with the consideration of available guidelines published by leading professional associations of radiotherapy and oncology (urological), research articles, and own experience.

show abstract

Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?

Cited by 5 publications

References 29 publications

Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy

Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy

Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications

Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021)

Contact Info

Product

Resources

About